File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

TitleEfficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
Authors
Issue Date8-Nov-2022
PublisherMassachusetts Medical Society
Citation
New England Journal of Medicine, 2022, v. 387, n. 21, p. 1957-1968 How to Cite?
Abstract

Background Bepirovirsen is an antisense oligonucleotide that targets all hepatitis B virus (HBV) messenger RNAs and acts to decrease levels of viral proteins. Methods We conducted a phase 2b, randomized, investigator-unblinded trial involving participants with chronic HBV infection who were receiving or not receiving nucleoside or nucleotide analogue (NA) therapy. Participants were randomly assigned (in a 3:3:3:1 ratio) to receive weekly subcutaneous injections of bepirovirsen at a dose of 300 mg for 24 weeks (group 1), bepirovirsen at a dose of 300 mg for 12 weeks then 150 mg for 12 weeks (group 2), bepirovirsen at a dose of 300 mg for 12 weeks then placebo for 12 weeks (group 3), or placebo for 12 weeks then bepirovirsen at a dose of 300 mg for 12 weeks (group 4). Groups 1, 2, and 3 received loading doses of bepirovirsen. The composite primary outcome was a hepatitis B surface antigen (HBsAg) level below the limit of detection and an HBV DNA level below the limit of quantification maintained for 24 weeks after the planned end of bepirovirsen treatment, without newly initiated antiviral medication. Results The intention-to-treat population comprised 457 participants (227 receiving NA therapy and 230 not receiving NA therapy). Among those receiving NA therapy, a primary-outcome event occurred in 6 participants (9%; 95% credible interval, 0 to 31) in group 1, in 6 (9%; 95% credible interval, 0 to 43) in group 2, in 2 (3%; 95% credible interval, 0 to 16) in group 3, and 0 (0%; post hoc credible interval, 0 to 8) in group 4. Among participants not receiving NA therapy, a primary-outcome event occurred in 7 participants (10%; 95% credible interval, 0 to 38), 4 (6%; 95% credible interval, 0 to 25), 1 (1%; post hoc credible interval, 0 to 6), and 0 (0%; post hoc credible interval, 0 to 8), respectively. During weeks 1 through 12, adverse events, including injection-site reactions, pyrexia, fatigue, and increased alanine aminotransferase levels, were more common with bepirovirsen (groups 1, 2, and 3) than with placebo (group 4). Conclusions In this phase 2b trial, bepirovirsen at a dose of 300 mg per week for 24 weeks resulted in sustained HBsAg and HBV DNA loss in 9 to 10% of participants with chronic HBV infection. Larger and longer trials are required to assess the efficacy and safety of bepirovirsen. (Funded by GSK; B-Clear ClinicalTrials.gov number, .)


Persistent Identifierhttp://hdl.handle.net/10722/331037
ISSN
2023 Impact Factor: 96.2
2023 SCImago Journal Rankings: 20.544
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYuen, MF-
dc.contributor.authorLim, SG-
dc.contributor.authorPlesniak, R-
dc.contributor.authorTsuji, K-
dc.contributor.authorJanssen, HLA-
dc.contributor.authorPojoga, C-
dc.contributor.authorGadano, A-
dc.contributor.authorPopescu, CP-
dc.contributor.authorStepanova, T-
dc.contributor.authorAsselah, T-
dc.contributor.authorDiaconescu, G-
dc.contributor.authorYim, HJ-
dc.contributor.authorHeo, J-
dc.contributor.authorJanczewska, E-
dc.contributor.authorWong, A-
dc.contributor.authorIdriz, N-
dc.contributor.authorImamura, M-
dc.contributor.authorRizzardini, G-
dc.contributor.authorTakaguchi, K-
dc.contributor.authorAndreone, P-
dc.contributor.authorArbune, M-
dc.contributor.authorHou, JL-
dc.contributor.authorPark, SJ-
dc.contributor.authorVata, A-
dc.contributor.authorCremer, J-
dc.contributor.authorElston, R-
dc.contributor.authorLukic, T-
dc.contributor.authorQuinn, G-
dc.contributor.authorMaynard, L-
dc.contributor.authorKendrick, S-
dc.contributor.authorPlein, H-
dc.contributor.authorCampbell, F-
dc.contributor.authorPaff, M-
dc.contributor.authorTheodore, D-
dc.contributor.authorB-Clear Study Grp-
dc.date.accessioned2023-09-21T06:52:14Z-
dc.date.available2023-09-21T06:52:14Z-
dc.date.issued2022-11-08-
dc.identifier.citationNew England Journal of Medicine, 2022, v. 387, n. 21, p. 1957-1968-
dc.identifier.issn0028-4793-
dc.identifier.urihttp://hdl.handle.net/10722/331037-
dc.description.abstract<p>Background Bepirovirsen is an antisense oligonucleotide that targets all hepatitis B virus (HBV) messenger RNAs and acts to decrease levels of viral proteins. Methods We conducted a phase 2b, randomized, investigator-unblinded trial involving participants with chronic HBV infection who were receiving or not receiving nucleoside or nucleotide analogue (NA) therapy. Participants were randomly assigned (in a 3:3:3:1 ratio) to receive weekly subcutaneous injections of bepirovirsen at a dose of 300 mg for 24 weeks (group 1), bepirovirsen at a dose of 300 mg for 12 weeks then 150 mg for 12 weeks (group 2), bepirovirsen at a dose of 300 mg for 12 weeks then placebo for 12 weeks (group 3), or placebo for 12 weeks then bepirovirsen at a dose of 300 mg for 12 weeks (group 4). Groups 1, 2, and 3 received loading doses of bepirovirsen. The composite primary outcome was a hepatitis B surface antigen (HBsAg) level below the limit of detection and an HBV DNA level below the limit of quantification maintained for 24 weeks after the planned end of bepirovirsen treatment, without newly initiated antiviral medication. Results The intention-to-treat population comprised 457 participants (227 receiving NA therapy and 230 not receiving NA therapy). Among those receiving NA therapy, a primary-outcome event occurred in 6 participants (9%; 95% credible interval, 0 to 31) in group 1, in 6 (9%; 95% credible interval, 0 to 43) in group 2, in 2 (3%; 95% credible interval, 0 to 16) in group 3, and 0 (0%; post hoc credible interval, 0 to 8) in group 4. Among participants not receiving NA therapy, a primary-outcome event occurred in 7 participants (10%; 95% credible interval, 0 to 38), 4 (6%; 95% credible interval, 0 to 25), 1 (1%; post hoc credible interval, 0 to 6), and 0 (0%; post hoc credible interval, 0 to 8), respectively. During weeks 1 through 12, adverse events, including injection-site reactions, pyrexia, fatigue, and increased alanine aminotransferase levels, were more common with bepirovirsen (groups 1, 2, and 3) than with placebo (group 4). Conclusions In this phase 2b trial, bepirovirsen at a dose of 300 mg per week for 24 weeks resulted in sustained HBsAg and HBV DNA loss in 9 to 10% of participants with chronic HBV infection. Larger and longer trials are required to assess the efficacy and safety of bepirovirsen. (Funded by GSK; B-Clear ClinicalTrials.gov number, .)<br></p>-
dc.languageeng-
dc.publisherMassachusetts Medical Society-
dc.relation.ispartofNew England Journal of Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleEfficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection-
dc.typeArticle-
dc.identifier.doi10.1056/NEJMoa2210027-
dc.identifier.pmid36346079-
dc.identifier.scopuseid_2-s2.0-85144409617-
dc.identifier.volume387-
dc.identifier.issue21-
dc.identifier.spage1957-
dc.identifier.epage1968-
dc.identifier.eissn1533-4406-
dc.identifier.isiWOS:000882488900001-
dc.publisher.placeWALTHAM-
dc.identifier.issnl0028-4793-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats